@article{072d71383d104cbf972beb364628b466,
title = "Brain MR radiomics to differentiate cognitive disorders",
abstract = "Objective: Subtle and gradual changes occur in the brain years before cognitive impairment due to age-related neurodegenerative disorders. The authors examined the utility of hippocampal texture analysis and volumetric features extracted from brain magnetic resonance (MR) data to differentiate between three cognitive groups (cognitively normal individuals, individuals with mild cognitive impairment, and individuals with Alzheimer{\textquoteright}s disease) and neuropsychological scores on the Clinical Dementia Rating (CDR) scale. Methods: Data from 173 uni que pati ents with 3-T T1-weighted MR images from the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative database were analyzed. A variety of texture and volumetric features were extracted from bilateral hippocampal regions and were used to perform binary classification of cognitive groups and CDR scores. The authors used diagonal quadratic discriminant analysis in a leave-one-out cross-validation scheme. Sensitivity, specificity, and area under the receiver operating characteristic curve were used to assess the performance of models. Results: The results show promise for hippocampal texture analysis to distinguish between no impairment and early stages of impairment. Volumetric features were more successful at differentiating between no impairment and advanced stages of impairment. Conclusions: MR radiomics may be a promising tool to classify various cognitive groups.",
author = "{Alzheimer{\textquoteright}s Disease Neuroimaging Initiative} and Sara Ranjbar and Velgos, {Stefanie N.} and Dueck, {Amylou C.} and Geda, {Yonas E.} and Mitchell, {J. Ross}",
note = "Funding Information: Data used in preparation of this article were obtained from the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this article. A complete listing of ADNI investigators is available online (http://adni.loni.usc.edu/wpcontent/ uploads/how_to_apply/ADNI_Acknowledgement_List.pdf). Supported by the National Center for Advancing Translational Sciences (grant UL1 TR000135), a component of NIH. Data collection and sharing for this study was funded by the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative (NIH grant U01 AG024904) and a Department of Defense Alzheimer{\textquoteright}s Disease Neuroimaging Initiative award (W81XWH-12-2-0012). The Alzheimer{\textquoteright}s Disease Neuroimaging Initiative is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through contributions from AbbVie, the Alzheimer{\textquoteright}s Association, the Alzheimer{\textquoteright}s Drug Discovery Foundation, Araclon Biotech, BioClinica, Biogen, Bristol-Myers Squibb, CereSpir, Cogstate, Eisai, Elan Pharmaceuticals, Eli Lilly, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research and Development, Johnson and Johnson Pharmaceutical Research and Development, Lumosity, Lundbeck, Merck, MesoScale Diagnostics, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals, Pfizer, Piramal Imaging, Servier, Takeda Pharmaceutical, and Transition Therapeutics. Funding Information: Supported by the National Center for Advancing Translational Sciences (grant UL1 TR000135), a component of NIH. Data collection and sharing for this study was funded by the Alzheimer?s Disease Neuroimaging Initiative (NIH grant U01 AG024904) and a Department of Defense Alzheimer?s Disease Neuroimaging Initiative award (W81XWH-12-2-0012). The Alzheimer?s Disease Neuroimaging Initiative is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through con?t?ributio?n?s from AbbVie, th?e? Alzheime?r??s Associat?i?on, the Alz?h?eimer?s Drug Discovery Foundation, Araclon Biotech, BioClinica, Biogen, Bristol-Myers Squibb, CereSpir, C?o?gstate, Eisai, Elan Pharmaceuticals, Eli Li?l?ly, EuroImmun?,? F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immuno-therapy Research and Development, Johnson and Johnson Pharmaceutical Research and Development, Lumosity, Lundbeck, Merck, MesoScale Diagnostics, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals, Pfizer, Piramal Imaging, Servier, Takeda Pharmaceutical, and Transition Therapeutics. Publisher Copyright: {\textcopyright} 2019, American Psychiatric Association. All rights reserved.",
year = "2019",
month = jul,
doi = "10.1176/appi.neuropsych.17120366",
language = "English (US)",
volume = "31",
pages = "210--219",
journal = "Journal of Neuropsychiatry and Clinical Neurosciences",
issn = "0895-0172",
publisher = "American Psychiatric Publishing Inc.",
number = "3",
}